Hepatitis C virus (HCV) infects 2-3% of the world population and intravenous drug consumption is the leading cause of transmission in industrialized countries. The unavailability of data on the molecular epidemiology of HCV infection in Portugal prompted the study of HCV subtypes circulating among i
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants
β Scribed by Gary P. Jeffrey; Gerry MacQuillan; Fern Chua; Sam Galhenage; Judith Bull; Emma Young; Gary Hulse; George O'Neil
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 150 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The prevalence of hepatitis C virus (HCV) infection amongst a group of intravenous drug users (IVDUs) resident in West Suffolk (East Anglia, England) was investigated and compared with the prevalence of infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV). In addition, both
This study describes the distribution of hepatitis C genotypes among 106 intravenous drug users and 949 non-drug users in Hong Kong. Genotypes were identified by multiplex RT-PCR targeting the core region of viral genome. The accuracy of this typing system in identifying genotypes 1b and 6a was asse
## Abstract The aim of this study was to describe the distribution of hepatitis C genotypes among intravenous drug users in northβeastern Poland. The study group included intravenous drug users recruited at a drug treatment center and a clinic for HIVβinfected patients. HCV infection was confirmed
The prevalence of delta virus infection was studied in 264 intravenous drug abusers (IVDAs) whose sera were found to be HBsAg positive between 1985 and 1987 and in 15 IVDAs from the period 1971-75, seven from 1976, 15 from 1979, and 37 from 1982. Delta markers were present in 41% of IVDAs with acute
This study assessed the effect of chronic hepatitis C virus (HCV) infection on the healthrelated quality of life (HRQOL) of injecting drug users, comparing the HRQOL of injecting drug users with and without chronic HCV infection. The study included 199 injecting drug users of more than 18 years of a